CytRx Corporation (NASDAQ:CYTR) Soars 19% On ongoing phase 1b aldoxorubicin combination studies Print E-mail
By Marilyn Mullen   
Tuesday, 05 May 2015 01:16
Biopharmaceutical research and development firm, CytRx Corporation (NASDAQ:CYTR), specializing in oncology, has confirmed an interim analysis from the two ongoing phase 1b aldoxorubicin combination studies combining aldoxorubicin with either gemcitabine or ifosfamide.
Read more...
 
Gilead Sciences, Inc.(NASDAQ:GILD)’s Shares Jump On Robust Earnings and Strong Guidance Print E-mail
By William Kent   
Friday, 01 May 2015 18:38
Undisputed leader in hepatitis C drugs market, Gilead Sciences, Inc. (NASDAQ:GILD), has come out with first-quarter financial results for the
year.
Read more...
 
Merck & Co., Inc. (NYSE:MRK) Reports Pivotal Data from Phase 3 Clinical Studies of ZERBAXA Print E-mail
By Marilyn Mullen   
Wednesday, 29 April 2015 16:54
Merck & Co., Inc.(NYSE:MRK) has confirmed that The Lancet and Clinical Infectious Diseases published online results from pivotal Phase 3 clinical studies of ZERBAXA for Injection in complicated urinary tract infections as well as complicated intra-abdominal infections.
Read more...
 
Amarin Corporation plc (ADR) (NASDAQ:AMRN) confirms Anchor CRL from FDA Print E-mail
By Marilyn Mullen   
Tuesday, 28 April 2015 13:47
Amarin Corporation plc (ADR) (NASDAQ:AMRN) has confirmed receiving the

Error. Page cannot be displayed. Please contact your service provider for more details. (20)

much waited Complete Response Letter (CRL) from U.S. Food and Drug Administration (FDA) for the Vascepa capsules ANCHOR trial supplemental New Drug Application (sNDA).
Read more...
 
Celladon Corp (NASDAQ:CLDN) Tanks 80% as Heart Treatment Fails In Trial Print E-mail
By Mary Davila   
Monday, 27 April 2015 18:41
Celladon Corp (NASDAQ:CLDN)’s shares plunged over 80% after the company said that the Phase 2b CUPID2 trial doesn’t meet primary as well as secondary endpoints.
Read more...
 
GW Pharma gets Orphan Drug Designation From Print E-mail
By Marilyn Mullen   
Friday, 24 April 2015 14:24
  GW Pharmaceuticals PLC - ADR (NASDAQ:GWPH) has confirmed that U.S. Food and Drug Administration has given orphan drug designation to the Cannabidiol (CBD) for using in treatment of newborn children having neonatal hypoxic-ischemic encephalopathy (NHIE).
Read more...
 
Gilead Sciences, Inc. (NASDAQ:GILD) confirms about Investigational and All-Oral Three-Drug Regimen of Sofosbuvir, GS-5816 and GS-9857 for Chronic Hepatitis C Print E-mail
By David Fowler   
Thursday, 23 April 2015 13:57
Gilead Sciences, Inc. (NASDAQ:GILD) has confirmed pre-clinical data as well as results from Phase 1 and Phase 2 studies which demonstrate development of an investigational all-oral as well as pan-genotypic regimen of Sovaldi. Sovaldi is the investigational NS5A inhibitor GS-5816 and GS-9857.
Read more...
 
Great Basin Scientific Inc. (NASDAQ:GBSN) gets nod from FDA for Group B Strep Molecular Diagnostic Test, Shares Soar Print E-mail
By David Fowler   
Wednesday, 22 April 2015 17:33
Molecular diagnostics company, Great Basin Scientific Inc. (NASDAQ:GBSN), has got clearance from U.S. Food and Drug Administration for the molecular diagnostic test for Group B Streptococcus (GBS).
Read more...
 
Calithera Biosciences Inc. (NASDAQ:CALA) Tumbles 10% On preclinical data of CB-839 Print E-mail
By William Kent   
Tuesday, 21 April 2015 14:24
Clinical-stage pharmaceutical firm, Calithera Biosciences Inc. (NASDAQ:CALA), has confirmed the preclinical data for the main anti-cancer therapeutic candidate, CB-839.
Read more...
 
The Medicines Company (NASDAQ:MDCO ): FDA gives approval to new formulation of MINOCIN for Injection Print E-mail
By William Kent   
Monday, 20 April 2015 13:52
The Medicines Company (NASDAQ:MDCO)’s shares tumbled over 5% despite the company said that U.S. Food and Drug Administration has given approval to a supplemental new drug application (sNDA) for the fresh formulation of MINOCIN for Injection.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 6 of 12

Newsletter

BMR:1